Urolithin A vs NAD+: Which Is Better for Longevity?
Should I buy urolithin A or NAD+ infusions?
Urolithin A scores 6.5 and direct NAD+ scores 5.0, and the gap is about human evidence rather than biology. Urolithin A has completed human trials with measured mitochondrial and immune endpoints. Direct NAD+ has one human pharmacokinetic study and no efficacy trial at all, at six to sixteen times the monthly cost.
- Urolithin A 6.5, direct NAD+ 5.0. The 1.5 point gap comes from human trial data, not from mechanism.
- Urolithin A's mitochondrial subrating is 7.0. Direct NAD+ scores 2.8 there, because no direct-NAD+ trial has measured a mitochondrial outcome in a person.
- Direct NAD+ rests on one human study, Grant 2019, and that study measured where infused NAD+ went, not whether anyone got better.
- Mitopure runs $50 to $100 a month. Clinic NAD+ infusions run an ESTIMATED $300 to $1,600 a month depending on session frequency.
- For felt energy, neither one has controlled human evidence. I ran Mitopure at 500 mg a day for about 90 days and noticed nothing.
- If your actual goal is raising NAD+, neither of these is the efficient buy. The oral precursors carry that data and get their own comparison.
At a Glance
Urolithin A
- Efficacy 2.7
- Breadth 3.0
- Evidence 2.8
- Speed 2.3
- Durability 2.5
- Bioindividuality 3.6
- Safety Risk 1.4
- Side Effects 1.4
- Cost 4.3
- Effort 1.3
- Opportunity Cost 2.0
- Dependency 1.5
- Reversibility 1.2
- Mitochondrial
- Anti Inflammatory
- Geriatric
- Muscle Growth
Oral gut-microbial metabolite that supports selective mitophagy. BioHarmony 6.5, worth trying.
NAD+ (Direct)
- Efficacy 2.5
- Breadth 2.8
- Evidence 2.7
- Speed 3.2
- Durability 2.0
- Bioindividuality 3.0
- Safety Risk 2.0
- Side Effects 3.0
- Cost 3.6
- Effort 3.8
- Opportunity Cost 3.2
- Dependency 2.0
- Reversibility 1.8
- Energy
- Longevity
- Metabolic Health
- Mitochondrial
The coenzyme itself, given by IV drip, injection, sublingual or nasal route. BioHarmony 5.0, neutral.
Head-to-Head Verdict
| Use Case | Winner | Rationale |
|---|---|---|
| Mitochondrial | Urolithin A | Urolithin A takes this 7.0 against 2.8, and it is the widest honest gap on the page. Andreux 2019 measured acylcarnitine shifts and mitochondrial gene-expression changes in people after regular dosing. No direct-NAD+ study has measured a mitochondrial outcome in a human, and Kory 2020 makes intact cellular uptake of infused NAD+ contested in the first place. |
| Healthspan | Urolithin A | Urolithin A 5.0 against 2.8. Neither score is impressive and neither buys you proven aging modification. The difference is that urolithin A's healthspan case rests on small completed human trials, while direct NAD+ has a strong age-decline story from Massudi 2012 and no human outcome trial for the route being sold. |
| Longevity | Urolithin A | Urolithin A 5.0 against 3.0. Ryu 2016 extended lifespan in C. elegans and improved muscle function in rodents, which is preclinical, and human lifespan evidence does not exist on either side. Direct NAD+ loses this row on delivery: the longevity pitch is real biology, and the one human study of the route showed rapid breakdown and urinary loss. |
| Cellular Senescence | Urolithin A | Urolithin A 4.0 against 2.4, and both are mechanism-grade scores. Neither side has a human senescence-marker endpoint. Urolithin A gets the row because Denk 2025 is a 50-person randomized trial that moved CD8+ immune-aging and fatty-acid oxidation endpoints in four weeks. Direct NAD+ has nothing human of any kind here. |
| Energy | Tie | Call this even, and understand that even means neither. Urolithin A scores 4.0 and direct NAD+ scores 3.0, and both rest on subjective reports rather than a controlled energy trial. Grant 2019 was pharmacokinetic. Urolithin A's own report calls subjective energy mixed and unproven. This is the headline claim for both products and the weakest row on the page. |
| Antioxidant | NAD+ (Direct) | Direct NAD+ takes this 2.4 against 1.0, and the win is worth almost nothing. NAD+ does feed redox balance and NADPH-dependent defenses, so the biochemistry is real. Urolithin A's own report states it is not primarily an antioxidant at all. Neither has a controlled human antioxidant outcome, so do not buy either product for this. |
| Cardiovascular | Tie | Even, and even means neither again. Urolithin A scores 3.0 and direct NAD+ scores 2.2. Hodzic Kuerec 2024 pooled five human studies and found no clear cardiovascular outcome effect for urolithin A. Direct NAD+ has no human cardiovascular trial at all. If heart risk is your reason for shopping, both of these are the wrong aisle. |
| Mood | Tie | Even at the bottom: urolithin A 1.0, direct NAD+ 2.2. Neither has a controlled human mood trial. The mood lift people describe after an IV belongs to the same-session infusion ritual, which is exactly why the NAD+ report scores it low despite the anecdotes. Urolithin A has no human mood endpoint evidence whatsoever. |
Cost Comparison
| Intervention | Monthly Cost | Notes |
|---|---|---|
| Urolithin A | $50 to $100 | Priced 2026-09-07, retail channel, extracted from the source report rather than estimated. That figure buys branded Mitopure at the studied 500 mg a day dose, which is the only form validated in the human RCTs. Generic urolithin A is cheaper and unvalidated, with real purity and label-claim problems, so the cheaper option is not the same purchase. |
| NAD+ (direct) | $300 to $1,600 | ESTIMATE, priced 2026-09-07, clinic session channel. The basis is that US clinics charge roughly $300 to $800 for a 500 mg NAD+ IV, priced here at one session a month at the low end and two sessions a month at the high end. Your actual bill depends entirely on how often a clinic tells you to come back, and the effect does not accumulate between visits. |
| The difference | Six to sixteen times more for the infusion | At the low end you are comparing $300 against $50. At the high end, $1,600 against $100. That is six to sixteen times the spend for the side with less human evidence, which is unusual enough to be the headline.A single month of infusions at the high end costs more than a full 16-week Mitopure trial, and 16 weeks is the assessment window urolithin A's own report asks for. Spend the money where a measurable endpoint exists. |
When to Switch
These two run on different clocks, and that is the first thing to fix. Direct NAD+ gives a first noticeable effect within about a day and its assessment window is 4 weeks. Urolithin A takes about 4 weeks for a first change, reaches full effect at 16 weeks, and asks for a 16-week window. So the drip feels like something immediately and the capsule feels like nothing for a month, which tells you almost nothing about which one works.
Move from NAD+ infusions to urolithin A when you have paid for a few sessions, the felt lift faded within days each time, and you want an endpoint you can measure: pick a marker, run 16 weeks of Mitopure at 500 mg a day, and stop if the marker does not move. That is the default on this page. Move the other way only if you have finished a full 16-week urolithin A trial with no change and you are deliberately buying the clinic experience with money you can spare, knowing no efficacy trial sits behind it.
There is no mechanism reason to run both. Mitophagy support and coenzyme refilling do not interact in any way the human data can show, so stacking them just doubles the bill.
Who Should Pick What?
Older or sedentary adult who suspects a mitochondrial bottleneck
Urolithin A
Mitochondrial subrating 7.0 against 2.8, and Liu 2022 studied adults aged 65 to 90 and found muscle-endurance plus biomarker signals. This is the population the human urolithin A evidence actually covers. Run 16 weeks, track something objective.
Your real goal is raising NAD+ levels
Tie
Neither of these. Urolithin A does not raise NAD+, and direct NAD+ has one human pharmacokinetic study showing rapid breakdown and urinary loss. The oral precursors NMN and NR carry the human NAD-raising data and cost a fraction of a drip. That comparison is its own page.
Fit, well-trained and metabolically healthy, chasing more energy
Tie
Neither. The energy row is a 4.0 against 3.0 tie with no controlled human trial on either side. I ran Mitopure at 500 mg a day for about 90 days and noticed no clear subjective effect, and I am already fit. The urolithin A trial signal skews toward sedentary or older adults.
Rebuilding after an illness or a hard training block
Urolithin A
This is the specific case I kept it on the bench for: recovery blocks, post-illness, after travel. Recovery-repair scores 4.0 and the immune signal from Denk 2025 landed in four weeks. Direct NAD+ has no human recovery or immune endpoint at all.
Cost is the binding constraint
Urolithin A
$50 to $100 a month against an ESTIMATED $300 to $1,600. You are paying six to sixteen times more for the option with one human study, and that study measured plumbing rather than payoff. The cheaper side also happens to be the better-evidenced side, which settles it.
You want the IV clinic ritual and can spare the money
NAD+ (Direct)
Honest answer: buy the experience, price it as an experience. The same-session clarity people describe tracks the drip ritual rather than a measured effect, and no controlled trial supports energy, longevity or cognition claims. Verify the clinic uses sterile, accurately dosed, properly compounded material.
Pregnant, nursing, or in active cancer treatment
Tie
Neither. Pregnancy and nursing are listed contraindications on both reports, urolithin A adds pediatric use and active oncology treatment without clinician supervision, and direct NAD+ adds active malignancy without oncology clearance. Neither has safety data in these groups.
Research Highlights
-
Mechanism Difference
These two mechanisms are complementary, not redundant, and they share no molecular target. Urolithin A supports selective mitophagy through the PINK1 and Parkin quality-control pathway, which tags damaged mitochondria for recycling.NAD+ is the central redox coenzyme and a consumed substrate for sirtuins, PARPs and CD38, so giving it directly aims to refill a pool rather than clean up a population. One clears broken units, the other supplies fuel and signaling currency. Complementary on paper still does not justify buying both, because the direct NAD+ route has no human efficacy data.
-
Safety Comparison
Urolithin A is the safer purchase. It scores 1.4 on safety risk and 1.4 on side effects, backed by short human RCTs, rodent toxicology and FDA GRAS food-ingredient status. Direct NAD+ scores 2.0 and 3.0 on the same two dimensions.The NAD+ hazards are procedural rather than intrinsic: rate-dependent flushing, nausea and chest tightness during infusion, plus contamination and dose-accuracy risk from compounded or research-chemical material. Both rule out pregnancy and nursing, and both want oncology clearance first.
-
Cost Comparison
Branded Mitopure runs $50 to $100 a month at the studied 500 mg a day dose, priced 2026-09-07 from retail. Clinic NAD+ infusions are an ESTIMATE of $300 to $1,600 a month, based on US clinics charging roughly $300 to $800 per 500 mg IV at one to two sessions a month.That is six to sixteen times the monthly spend for the side with one human pharmacokinetic study and zero efficacy trials. A single high-end month of infusions costs more than the entire 16-week urolithin A trial its own report asks you to run.
-
Evidence Grade
The evidence grades are not close. Urolithin A has completed human randomized trials: Andreux 2019 on safety and mitochondrial biomarkers, Liu 2022 in adults aged 65 to 90, Denk 2025 in 50 people on immune aging, and a 2024 systematic review of five human studies.Direct NAD+ has one human study, Grant 2019, which tracked plasma and urine NAD+ during a 6-hour infusion. It measured where the molecule went, not whether anyone improved. Zero controlled efficacy trials exist for direct NAD+ by any route.
-
Editorial Verdict
Urolithin A wins this comparison 6.5 to 5.0, and the reason is human data rather than better biology. It takes mitochondrial 7.0 to 2.8, healthspan 5.0 to 2.8, longevity 5.0 to 3.0 and cellular senescence 4.0 to 2.4, while costing six to sixteen times less.Be clear about what winning means here. Both sides tie at the bottom on energy, cardiovascular and mood, where neither has controlled human evidence and neither earns your money. Buy urolithin A for a defined 16-week mitochondrial trial, or buy nothing.
Frequently Asked Questions
- Is urolithin A better than NAD+ infusions?
- For every use case on this page except a mechanism-only antioxidant claim, yes. Urolithin A scores 6.5 against 5.0 and takes mitochondrial 7.0 to 2.8. The difference is completed human trials on one side and a single pharmacokinetic study on the other. Urolithin A also costs six to sixteen times less per month.
- Do urolithin A and NAD+ do the same thing?
- No. Urolithin A supports selective mitophagy through the PINK1 and Parkin pathway, which clears damaged mitochondria. NAD+ is the central redox coenzyme and a substrate consumed by sirtuins, PARPs and CD38. They share no molecular target. The mechanisms are complementary in theory, which still does not make buying both a good idea.
- Which one is cheaper?
- Urolithin A, by a wide margin. Branded Mitopure runs $50 to $100 a month at 500 mg a day, priced 2026-09-07. Clinic NAD+ infusions are an ESTIMATED $300 to $1,600 a month, based on roughly $300 to $800 per 500 mg IV at one to two sessions monthly. One high-end infusion month costs more than a full 16-week urolithin A trial.
- How long before I know if either is working?
- Direct NAD+ gives a first noticeable effect within about a day and its assessment window is 4 weeks. Urolithin A takes about 4 weeks for a first change, reaches full effect at 16 weeks, and asks for a 16-week window. Judge urolithin A at 16 weeks against a marker you picked in advance, not on how you feel in week two.
- Will NAD+ infusions give me more energy than urolithin A?
- Neither has controlled human evidence for energy. The subratings are 4.0 for urolithin A and 3.0 for direct NAD+, and both rest on subjective reports. The same-session lift after an IV tracks the drip ritual, and it fades. I ran Mitopure at 500 mg a day for about 90 days and noticed no clear subjective effect.
- If I want to raise my NAD+ levels, should I get the infusion?
- Not based on the evidence. The one human study of infused NAD+ showed rapid breakdown and urinary loss, and intact uptake into cells is contested because the transporter sits on the mitochondrion rather than the cell surface. The oral precursors NMN and NR raise blood NAD+ in human trials and cost a fraction of a drip.
- Can I take both?
- There is no mechanism reason to. Mitophagy support and coenzyme refilling do not interact in any way the human data can show, so running both mostly doubles the bill. If you are going to spend once, spend it on the side with completed human trials and a measurable 16-week endpoint.
- Who should avoid these?
- Anyone pregnant or nursing, on either. Urolithin A adds pediatric use, active oncology treatment without clinician supervision, and unverified generic product with no label-claim testing.Direct NAD+ adds active malignancy without oncology clearance, severe cardiovascular disease given the infusion-rate flushing and chest tightness, and any research-chemical material for injection. Neither substitutes for real treatment.
- Does the generic urolithin A work as well as Mitopure?
- Unknown, and that is the honest answer. Every published human trial used Mitopure, the micronized preparation from Amazentis and Timeline. Generic urolithin A has documented purity and label-claim problems, and equivalence has never been established. Buying the cheap version and expecting the trial result is the common mistake in this category.
Evidence Sources
- RCT The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans (2019) First-in-human urolithin A study. Safety, bioavailability, acylcarnitine shifts and mitochondrial gene-expression effects.
- RCT Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults (2022) Older-adult RCT. Muscle-endurance and biomarker signals, but 6-minute walk and maximal ATP production were not clearly significant against placebo.
- RCT Effect of the mitophagy inducer urolithin A on age-related immune decline (2025) 50-person RCT. 1000 mg a day for 4 weeks shifted CD8+ immune-aging and fatty-acid oxidation endpoints.
- Systematic review Targeting aging with urolithin A in humans: a systematic review (2024) Five human studies, 250 healthy individuals. Anti-inflammatory and mitochondrial marker signals, insufficient evidence for broad physical-function or cardiovascular claims.
- Systematic review The effects of urolithin A supplementation on muscle strength, muscle mass and physical performance in humans (2025) Preprint synthesis of three randomized trials. Pooled 6-minute walk estimate crossed null; evidence called insufficient for current muscle-function use.
- Preclinical Urolithin A induces mitophagy and prolongs lifespan in C. elegans and increases muscle function in rodents (2016) Foundational preclinical mitophagy paper. Lifespan and muscle-function signals in worms and rodents, not humans.
- RCT A pilot study of the plasma and urine NAD+ metabolome during a 6-hour intravenous infusion of NAD+ in healthy men (2019) The cornerstone direct-NAD+ human study. Pharmacokinetic, not efficacy. Showed rapid breakdown and urinary loss.
- Preclinical SLC25A51 is a mammalian mitochondrial NAD+ transporter (2020) The mitochondrial NAD+ pool is loaded by a dedicated carrier sitting on the mitochondrion rather than the cell surface.
- Preclinical MCART1 and SLC25A51 are required for mitochondrial NAD transport (2020) Confirms NAD+ does not freely cross membranes. Mechanistic basis for why intact uptake of infused NAD+ stays contested.
- Observational Age-associated changes in oxidative stress and NAD+ metabolism in human tissue (2012) Establishes the age-related NAD+ decline that motivates trying to restore it.
- Preclinical CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism (2016) Mechanism of the age decline and the ongoing NAD+ consumption that a one-time bolus does not durably change.
- Review Therapeutic potential of NAD-boosting molecules: the in vivo evidence (2018) Review of the NAD-restoration hypothesis that the direct-administration market relies on.
- RCT Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults (2018) Precursor context only. An RCT showing durable NAD+ elevation by the oral precursor route, which direct NAD+ has never demonstrated.
- Preclinical Safety assessment of Urolithin A, Food and Chemical Toxicology (2017) Rodent toxicology and genotoxicity assessment. High no-observed-adverse-effect level, no target-organ toxicity at tested doses.
Glossary
Quick reference for the medical and technical terms used in this comparison.
- Mitophagy Selective Mitochondrial Autophagy
- The cell's process for tagging and recycling damaged mitochondria. Narrower than general autophagy. This is urolithin A's whole mechanism.
- PINK1 / Parkin PTEN-Induced Kinase 1 and Parkin Pathway
- The mitochondrial quality-control pathway that flags damaged mitochondria for cleanup. The route urolithin A acts through.
- NAD+ Nicotinamide Adenine Dinucleotide
- The central redox coenzyme of energy metabolism, also consumed by sirtuins, PARPs and CD38. Tissue levels fall with age.
- Mitopure Micronized Urolithin A (Amazentis / Timeline)
- The only urolithin A preparation used across the published human RCTs. Generic capsule equivalence has not been established.
- SLC25A51 Mitochondrial NAD+ Transporter
- The carrier that loads the mitochondrial NAD+ pool. It sits on the mitochondrion, not the cell surface, which is why intact uptake of infused NAD+ is contested.
- CD38 Cyclic ADP Ribose Hydrolase
- An enzyme that consumes NAD+ and drives its decline with age. Part of why a one-time infusion does not change the pool durably.
- PK study Pharmacokinetic Study
- A study of where a substance goes and how fast it clears, rather than whether it helps. The single human direct-NAD+ study is this kind.
- Ellagitannins Pomegranate and Walnut Polyphenols
- Food polyphenols that gut bacteria convert into urolithin A. Many adults are low or non-producers, which is why the supplement exists.
- GRAS Generally Recognized As Safe
- A US food-ingredient safety status. Urolithin A holds GRAS Notice 791. This is not drug approval, and direct NAD+ has no equivalent status for these uses.
